logo
How an Indigenous health centre in Montreal is making care more welcoming

How an Indigenous health centre in Montreal is making care more welcoming

Yahoo21-06-2025
As Shirley Pien-Bérubé walks through the halls of the Indigenous Health Centre of Tio'tia:ke, she pauses to point out all the ways the Montreal-based clinic has grown since it opened in 2023.
"Our services have expanded so much," she said. "We have a diabetic foot-care clinic, we have an optometry clinic, physiotherapy, mental health, clinical psychologist, addictions worker, a spiritual healer."
Just inside the main entrance, a table is set up with sage and sweetgrass. Patients are invited to smudge or make their own medicine bundles. Care here is offered in several Indigenous languages, including Inuktitut and Cree.
Pien-Bérubé works as a health navigator, accompanying patients and advocating for them within the health-care system. She says that's just one of the services offered here.
The clinic aims to close gaps in health outcomes for Indigenous patients, which was one of the 94 calls to action of Canada's Truth and Reconciliation Commission (TRC). Clinic staff also work to overcome deep-rooted mistrust in the health-care system. Data from a recent Statistics Canada survey found about one in five Indigenous people reported experiencing unfair treatment, racism or discrimination from a health-care professional over the previous year.
Pien-Bérubé says patients at her clinic can feel safe and understood.
"They are finally being heard — after how many centuries? We are finally being heard," she said.
WATCH | Inside the Montreal clinic:
10 years after TRC's calls to action
It's been 10 years since the Truth and Reconciliation Commission, which looked to document the impact of residential schools, released its final report. In it, the commissioners pointed to "troubling gaps in health outcomes between Aboriginal and non-Aboriginal Canadians."
Those include disparities in the rates of infant mortality, diabetes and suicide.
Seven of the TRC's 94 calls to action focused on health, including a call to identify and close gaps in health outcomes, funding for existing and new Indigenous healing centres and recognizing the value of Indigenous healing practices.
Fay Virginia Desjarlais, the family violence prevention co-ordinator at the Indigenous Health Centre of Tio'tia:ke, says the clinic is a sign there has been some progress.
"There were gaps in the health system to really understand the needs of the Indigenous people living in Montreal," she said. "People didn't feel safe. A lot of advocates, elders and different organizations came together to say 'We need to do something.' "
Desjarlais says hospitals and other health-care settings can be unwelcoming for many Indigenous people. She has seen patients face discrimination and racism, and has been through it herself with a family doctor.
"I'm diabetic and I was explaining that I'm not feeling well," she said, adding that when she described her symptoms, the doctor replied that when people feel that way, "that's because you're drinking."
She says the doctor then dropped her as a patient because she had missed a single appointment.
"I couldn't believe it," Desjarlais said.
Improving access to health care
According to the website Indigenous Watchdog, which tracks progress on the calls to action, while four of the seven calls related to health are in progress, three have stalled, and none are complete.
The site's publisher, Douglas Sinclair, says the call to identify and close gaps around health outcomes has stalled in part due to a lack of access to government data.
"There's just no political will across the country to sort of co-ordinate activities to identify that information and make it available," Sinclair said.
"You can't develop policy if you're working in a vacuum."
The federal government tracks its response to the recommendations on its website. It includes a health inequalities data tool available for users to visualise and "understand the size of inequities in social determinants of health and health outcomes."
Sinclair says that where there has been progress, it hasn't been enough. He says access to health care remains a major issue for a lot of communities.
Building treatment centres in the North
In Iqaluit, Nunavut, an addictions and trauma treatment centre called Aqqusariaq is currently under construction that will allow people to receive culturally-based treatment in the territory, in Inuktitut, rather than having to travel south.
"Travelling all the way down south to have to take part in treatment and care, you are being removed from your language and culture," said Kylie Aglukark, program director with addictions and trauma at Nunavut Tunngavik Incorporated, a treaty organization that represents Inuit in Nunavut.
"I'm hopeful that once this is up and running that we have an opportunity to build centres in each of Nunavut's regions," she said.
Beyond that, Aglukark wants to build up the Inuit workforce for the centre and other services and to establish more treatment centres in more communities.
"It's very important for Inuit to lead and have that opportunity to provide the services in Inuktitut," she said.
Dr. Terri Aldred, academic lead with the National Collaborating Centre for Indigenous Health, says progress on the calls to action around health has been "moderate."
While she's impressed with new Indigenous health clinics and healing centres like the ones in Montreal and Iqaluit that are "rooted in our ways of knowing and being," Aldred says such projects need to be scaled up to meet the need. She says they also need sustainable, long-term funding.
"Indigenous people that are able to access those services will start to have a different relationship with accessing health care," she said. "And we'll be able to build trust with those providers, and we'll have a positive ripple effect.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Foundation for Sarcoidosis Research Announces Launch of Enhanced Sarcoidosis Data Registry
Foundation for Sarcoidosis Research Announces Launch of Enhanced Sarcoidosis Data Registry

Yahoo

timean hour ago

  • Yahoo

Foundation for Sarcoidosis Research Announces Launch of Enhanced Sarcoidosis Data Registry

CHICAGO, July 01, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those affected, is proud to announce the launch of a new and enhanced version of the FSR-SARC Registry, the Sarcoidosis Advanced Registry for Cures. The FSR-SARC Registry is an IRB-approved, longitudinal, patient-powered database designed to accelerate sarcoidosis research by collecting critical insights on diagnosis, organ manifestation, treatments, symptoms, and impacts on quality of life. With nearly 7,000 participants from 68 different countries to date, the Registry is a cornerstone of FSR's mission to advance understanding and treatment of this complex and often misunderstood disease. The upgraded FSR-SARC Registry introduces a new, user-friendly platform (in partnership with Across Healthcare) with expanded features to maximize the impact of patient participation. Participants can now more easily share their experiences, update their information, and contribute to a growing body of knowledge that supports both clinical research and improved patient outcomes. Key Features and Benefits of the New FSR-SARC Registry: Enhanced Data Collection: The registry now captures even more comprehensive information on patients impacted by sarcoidosis. In addition to questionnaires and surveys, participants receiving care in the U.S. can link the Registry directly to their provider's patient portal. Improved Security and Privacy: Hosted on Across Healthcare's HIPAA-compliant platform, the Registry ensures that all personal health information is encrypted, securely stored, and only shared in de-identified form with approved researchers. Empowering Patient Voices: By enabling patients and caregivers to self-report their experiences, the registry provides critical insights into the variability, progression, and burden of sarcoidosis, informing future research and care recommendations. Facilitating Research and Clinical Trials: The registry connects interested patients to IRB-approved research opportunities based on both their eligibility and proximity to trial sites, helping to stimulate hypothesis-driven research and support the development of new treatments. Commitment to Representation and Access: FSR remains dedicated to expanding the variety of Registry participants and ensuring representation of all sarcoidosis patients. 'FSR is committed to empowering patients and accelerating research through the FSR-SARC Registry. We are immensely grateful for the extraordinary commitment of the sarcoidosis community in giving of their time and insights to inform and drive sarcoidosis research,' said Mary McGowan, President and CEO of FSR. 'Now in its tenth year, the Registry has been one of our most powerful tools to elevate patient voices in the advancement of sarcoidosis research. The enhanced surveys and platform represent a significant step forward in our efforts to drive innovation elevate patient-centered drug development, and improve patient outcomes for all impacted by sarcoidosis.' Participation in the FSR-SARC Registry is voluntary, confidential, and open to all individuals living with sarcoidosis or their caregivers. By joining, participants help shape the future of sarcoidosis research and care. For more information about the FSR-SARC Registry and to sign up, please visit About Sarcoidosis Sarcoidosis is a rare inflammatory disease characterized by granulomas—tiny clumps of inflammatory cells—that can form in one or more organs. 90% of patients living with sarcoidosis have lung involvement. Despite advances in research, sarcoidosis remains challenging to diagnose, with limited treatment options and no known cure. Approximately 175,000 people live with sarcoidosis in the United States. About the Foundation for Sarcoidosis Research The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those living with the disease through research, education, and support. For more information about FSR and its community programs, visit: Media Contact: Cathi Davis, Director of Communications and Marketing Foundation for Sarcoidosis Research cathi@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million
Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million

Yahoo

timean hour ago

  • Yahoo

Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million

NEW YORK (AP) — Anne Wojcicki's bid to buy 23andMe, the genetic testing company she cofounded nearly 20 years ago, has received the court greenlight. That means Wojcicki's nonprofit TTAM Research Institute will purchase 'substantially all' of San Francisco-based 23andMe's assets for $305 million. The transaction — which arrives more than three months after 23andMe filed for Chapter 11 bankruptcy — is set to officially close in the coming weeks. 'I am thrilled that TTAM will be able to build on the mission of 23andMe to help people access, understand and benefit from the human genome," Wojcicki said in a statement Monday — later adding that, "the future of health care belongs to all of us.' The sale, which was approved by U.S. Bankruptcy Judge Brian C. Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe's assets for $256 million in May. But Wojcicki's nonprofit later topped that offer, winning the final round of bidding held last month. Under the deal, TTAM will acquire 23andMe's signature 'Personal Genome Service" provided through the company's saliva-based DNA testing kits — as well as research operations and its Lemonaid Health subsidiary, a telehealth services provider that 23andMe previously planned to wind down. Wojcicki had worked to take 23andMe private for some time. With the company struggling to find a profitable business model since going public in 2021, she's maintained that it would operate better outside market pressures. But that endeavor proved to be tumultuous — notably in September of last year, when all of 23andMe's independent directors resigned from its board citing a 'clear' difference of opinion with Wojcicki on the company's future following drawn-out negotiations. Leading up to 23andMe's March bankruptcy filing, subsequent efforts from Wojcicki to acquire the company were unsuccessful. And when 23andMe filed for Chapter 11 in late March, Wojcicki resigned as CEO — noting at the time that she was stepping down to be 'in the best position' as an independent bidder. Now that Wojcicki's nonprofit will acquire 23andMe, it's unclear whether the co-founder will step back into the CEO seat. But despite stepping down from the top post months ago, Wojcicki has remained on the company's board throughout the bankruptcy process. Beyond financial strains leading up to 23andMe's bankruptcy, privacy concerns related to customers' genetic information also emerged — dating back to even before the bankruptcy process with a 2023 data breach. But concern what new ownership could mean for 23andMe users' personal data has bubbled up in recent months. The genetic testing business had about 13 million customers at the time of its sale hearing, court documents note. In June, 27 states and the District of Columbia filed a lawsuit seeking to block the sale of personal genetic data by 23andMe without customer consent. And in a memorandum opinion outlining his approval 23andMe's sale to TTAM on Friday, Walsh acknowledged these states' objections to the acquisition — but that noted many had since been resolved. Still, California, Kentucky, Tennessee, Texas, and Utah 'remain actively opposed to the sale." In a statement to Politico on Monday, California Attorney General Rob Bonta's office maintained that 23andMe's sale 'does not comply' with genetic privacy law in the state — and said it was 'disappointed' with the court's approval, adding that it was evaluating next steps. The Associated Press reached out to Bonta's office and 23andMe for further comments on Tuesday. When announcing its intended sale to Wojcicki's nonprofit last month, 23andMe confirmed that TTAM 'has affirmed its commitment' to comply with the company privacy policies and applicable law. That means TTAM will honor existing policies around consumer data, the company said, which includes allowing users to delete their data and 'opt out' of research. All customers will be emailed at least two business days before the acquisition closes — with details on TTAM's privacy commitments and instructions on how to delete data or opt out of research, 23andMe said. The company added that TTAM will offer customers two years of Experian identity theft monitoring at no cost. 23andMe reiterated those privacy policies on Monday. And Wojcicki added that, 'Core to my beliefs is that individuals should be empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish."

Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million
Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million

Yahoo

timean hour ago

  • Yahoo

Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million

NEW YORK (AP) — Anne Wojcicki's bid to buy 23andMe, the genetic testing company she cofounded nearly 20 years ago, has received the court greenlight. That means Wojcicki's nonprofit TTAM Research Institute will purchase 'substantially all' of San Francisco-based 23andMe's assets for $305 million. The transaction — which arrives more than three months after 23andMe filed for Chapter 11 bankruptcy — is set to officially close in the coming weeks. 'I am thrilled that TTAM will be able to build on the mission of 23andMe to help people access, understand and benefit from the human genome," Wojcicki said in a statement Monday — later adding that, "the future of health care belongs to all of us.' The sale, which was approved by U.S. Bankruptcy Judge Brian C. Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe's assets for $256 million in May. But Wojcicki's nonprofit later topped that offer, winning the final round of bidding held last month. Under the deal, TTAM will acquire 23andMe's signature 'Personal Genome Service" provided through the company's saliva-based DNA testing kits — as well as research operations and its Lemonaid Health subsidiary, a telehealth services provider that 23andMe previously planned to wind down. Wojcicki had worked to take 23andMe private for some time. With the company struggling to find a profitable business model since going public in 2021, she's maintained that it would operate better outside market pressures. But that endeavor proved to be tumultuous — notably in September of last year, when all of 23andMe's independent directors resigned from its board citing a 'clear' difference of opinion with Wojcicki on the company's future following drawn-out negotiations. Leading up to 23andMe's March bankruptcy filing, subsequent efforts from Wojcicki to acquire the company were unsuccessful. And when 23andMe filed for Chapter 11 in late March, Wojcicki resigned as CEO — noting at the time that she was stepping down to be 'in the best position' as an independent bidder. Now that Wojcicki's nonprofit will acquire 23andMe, it's unclear whether the co-founder will step back into the CEO seat. But despite stepping down from the top post months ago, Wojcicki has remained on the company's board throughout the bankruptcy process. Beyond financial strains leading up to 23andMe's bankruptcy, privacy concerns related to customers' genetic information also emerged — dating back to even before the bankruptcy process with a 2023 data breach. But concern what new ownership could mean for 23andMe users' personal data has bubbled up in recent months. The genetic testing business had about 13 million customers at the time of its sale hearing, court documents note. In June, 27 states and the District of Columbia filed a lawsuit seeking to block the sale of personal genetic data by 23andMe without customer consent. And in a memorandum opinion outlining his approval 23andMe's sale to TTAM on Friday, Walsh acknowledged these states' objections to the acquisition — but that noted many had since been resolved. Still, California, Kentucky, Tennessee, Texas, and Utah 'remain actively opposed to the sale." In a statement to Politico on Monday, California Attorney General Rob Bonta's office maintained that 23andMe's sale 'does not comply' with genetic privacy law in the state — and said it was 'disappointed' with the court's approval, adding that it was evaluating next steps. The Associated Press reached out to Bonta's office and 23andMe for further comments on Tuesday. When announcing its intended sale to Wojcicki's nonprofit last month, 23andMe confirmed that TTAM 'has affirmed its commitment' to comply with the company privacy policies and applicable law. That means TTAM will honor existing policies around consumer data, the company said, which includes allowing users to delete their data and 'opt out' of research. All customers will be emailed at least two business days before the acquisition closes — with details on TTAM's privacy commitments and instructions on how to delete data or opt out of research, 23andMe said. The company added that TTAM will offer customers two years of Experian identity theft monitoring at no cost. 23andMe reiterated those privacy policies on Monday. And Wojcicki added that, 'Core to my beliefs is that individuals should be empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish." Wyatte Grantham-philips, The Associated Press

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store